I

    Inhibrx Biosciences, Inc. (INBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $126.70
    +3.29 (+2.67%)

    Market Cap: $1.82B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(5/10)
    Avg Surprise
    +812.98%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-2.14
    Range$-2.14 - $-2.14
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-1.44+32.7%
    60d ago$-2.39-11.7%
    30d ago$-2.39-11.7%
    7d ago$-2.39-11.7%
    Current$-2.14
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Dec 31, 2026
    EPS Consensus$-3.31
    Range$-3.31 - $-3.31
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-3.31---
    Sep 26EST
    		-$-2.14---
    Jun 26
    		$-2.34$-2.50+6.40%Beat-26.5%
    Mar 26
    		$-2.15$-1.20-79.17%Miss+23.2%
    Dec 25
    		$-2.11$-1.63-29.45%Miss+31.7%
    Sep 25
    		$-2.28$-1.72-32.56%Miss+19.7%
    Jun 25
    		$-1.85$-2.60+28.85%Beat-101.5%
    Mar 25
    		$-2.80$-3.12+10.26%Beat-94.4%
    Dec 24
    		$-3.09$-1.44-114.58%Miss-
    Sep 24
    		$-2.84$-3.70+23.24%Beat-
    Jun 24
    		$125.48$-1.52+8355.26%Beat-
    Mar 24
    		$-1.44$-1.04-38.46%Miss-

    Key Metrics

    Valuation
    P/E Ratio-14.27EV/EBITDA0.02x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1774.00%ROIC1370.65%
    Financial Health
    Debt/Equity-3.33xInterest Coverage125.28x
    Current Ratio5.07xQuick Ratio5.07x
    Trading Statistics
    Beta3.52Avg Volume277.10K
    52-Week High$155.2952-Week Low$26.19

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$112.59
    SMA 20$101.45
    SMA 50$94.86
    SMA 200$88.02
    EMA 10$114.75
    EMA 20$106.09
    EMA 50$98.61
    EMA 200$83.66

    MACD

    Line: 9.21Signal: 5.76Hist: 3.45

    ADX

    ADX: 24.1+DI: 35.1-DI: 13.7

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down8.0
    PSAR$102.15

    Bollinger Bands

    Upper Band$131.18
    Lower Band$71.73
    %B Position5860%(Upper)
    Band Width0.92

    RSI (14-Day)

    Overbought
    75.5

    Momentum Oscillators

    Stoch %K86.2
    Stoch %D86.7
    Williams %R-9.4
    ROC (10d)37.7%
    Momentum34.69
    CCI (20d)143.6
    MFI (14d)59.1

    Volatility Measures

    ATR (14d)$7.64(6.0%)
    StdDev (20d)14.86
    Hist Vol78.8%(High)

    Volume Flow

    VWAP$125.72
    OBV20.2M
    AD Line6.4M
    CMF (20d)0.319

    Volume Metrics

    Avg Vol (20d)284.2K
    Vol Ratio1.4x
    VWMA (20d)$103.84

    Pivot Points

    R3$133.17
    R2$129.60
    R1$126.51
    Pivot Point$122.94
    S1$119.85
    S2$116.28
    S3$113.19

    Advanced Oscillators

    TSI38.24
    Ultimate Osc69.6
    KST254.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$1.30M$0$100,000$0$100,000$0$1.63M$119,000
    Cost of Revenue$0$0$564,000$0$0$0$689,000$0$0$0$298,000$0
    Gross Profit$0$0$-564,000$0$1.30M$0$100,000$0$100,000$0$1.34M$119,000
    Operating Expenses$32.15M$30.93M$30.92M$33.81M$28.69M$42.90M$50.03M$46.80M$161.00M$73.83M$89.63M$45.95M
    R&D$23.90M$25.22M$25.35M$28.54M$22.27M$36.88M$33.37M$38.89M$67.63M$63.85M$81.84M$38.06M
    SG&A$8.25M$5.71M$5.57M$5.28M$6.42M$6.02M$16.66M$7.90M$93.37M$9.97M$7.83M$7.89M
    Operating Income$-32,149,000$-30,927,000$-30,923,000$-33,812,000$-27,389,000$-42,901,000$-49,928,000$-46,797,000$-160,898,000$-73,825,000$-88,289,000$-45,827,000
    Interest Income$1.26M$1.01M$1.31M$1.78M$2.12M$2.33M$2.00M$2.89M$2.74M$3.30M$0$2.32M
    Interest Expense$5.69M$3.51M$3.19M$3.18M$3.14M$2.69M$0$0$5.36M$8.13M$8.22M$8.15M
    Income Before Tax$-36,647,000$-33,441,000$-32,834,000$-35,256,000$-28,652,000$-43,311,000$-47,865,000$-43,864,000$1.86B$-78,710,000$-93,608,000$-51,787,000
    Income Tax Expense$3,000$0$0$0$2,000$0$0$0$2,000$0$-4,000$2,000
    Net Income$-36,650,000$-33,441,000$-32,834,000$-35,256,000$-28,654,000$-43,311,000$-47,865,000$-43,864,000$1.86B$-78,710,000$-93,604,000$-51,789,000
    EBITDA$-30,403,000$-29,670,000$-29,756,000$-32,637,000$-26,348,000$-41,743,000$-49,179,000$-45,996,000$1.86B$-72,282,000$-87,991,000$-44,419,000
    EBIT$-32,217,000$-30,939,000$-30,962,000$-33,858,000$-27,635,000$-42,951,000$-49,868,000$-46,756,000$1.86B$-73,884,000$-88,289,000$-45,962,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INBX

    News

    Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus

    Inhibrx Biosciences (INBX) reported a wider net loss in Q2 2026, yet its shares have seen significant gains year-to-date and over the last year. The company's negative price-to-book ratio of -27.5x indicates that its valuation is driven by future drug development potential rather than current net assets, due to liabilities exceeding assets. Investors are advised to consider both the potential rewards and risks, including clinical trial setbacks or equity dilution.

    Sahm•8/22/26•
    Neutral

    Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325

    Stifel has reiterated its Buy rating for Inhibrx Biosciences (INBX.US) and maintained a target price of $325. This indicates Stifel's continued positive outlook on the company's stock performance.

    Moomoo•8/22/26•
    Bullish

    Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com

    Stifel has reiterated its Buy rating on Inhibrx Biosciences (NASDAQ: INBX) with a $325.00 price target, noting a substantial upside from the current price. The firm's positive outlook is based on upcoming randomized durability data for INBRX-106, strong management insights into the drug's mechanism, and recent financial and regulatory progress including an expanded credit facility and the FDA's acceptance of ozekibart's Biologics License Application. Despite a significant 310% return over the past year, InvestingPro data suggests the shares may be overvalued.

    Investing.com UK•8/21/26•
    Bullish

    Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com

    Stifel maintained its Buy rating on Inhibrx Biosciences (NASDAQ: INBX) with a $325.00 price target, despite the stock's significant 310% return over the past year and potential overvaluation. The firm anticipates strong potential ahead of randomized durability data for INBRX-106 next month and noted Inhibrx's recent credit facility expansion and FDA acceptance of its Biologics License Application for ozekibart, a potential first-in-class treatment for chondrosarcoma.

    Investing.com Canada•8/21/26•
    Bullish

    Western Standard LLC Takes $4.45 Million Position in Inhibrx Biosciences, Inc. $INBX

    Western Standard LLC has acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX), purchasing 47,000 shares valued at approximately $4.45 million, making it the fund's 19th largest holding. Despite this institutional interest, analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $150. Inhibrx Biosciences recently reported a quarterly loss of $2.34 per share, missing consensus estimates.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Frequently Asked Questions About INBX

    Does INBX pay dividends?
    Inhibrx Biosciences, Inc. (INBX) does not currently pay a regular dividend.
    What is INBX's market cap?
    Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.82B with a current stock price of $126.70.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In